Oruka Therapeutics, Inc. ORKA

Oruka Therapeutics' (ORKA) lead program of long-acting IL-23 in moderate-to-severe psoriasis maintai

Oruka Therapeutics recently reported positive Week 28 data from its EVERLAST-A Phase 2a trial of ORKA-001 in moderate-to-severe plaque psoriasis, showing deepening clinical responses and a safety profile consistent with the IL-23p19 class. An interesting aspect is that placebo patients who later crossed over to ORKA-001 achieved similar response patterns, underscoring the drug’s potential effect even after delayed initiation. Next, we’ll examine how ORKA-001’s high PASI 100 and PASI 90...